530
Views
45
CrossRef citations to date
0
Altmetric
Reviews

A structural biology view of target drugability

, PhD & , PhD
Pages 391-401 | Published online: 26 Mar 2008
 

Abstract

Background: With long and costly drug development times there is a need in the pharmaceutical industry to prioritize targets early in the drug discovery process. One of the possible criteria is ‘protein drugability’, a term with multiple understandings in the literature. Among others, it is the likelihood of finding a selective, low-molecular weight molecule that binds with high affinity to the target. Objective: Which methods are available for drugability prediction? What can be achieved by such predictions and how can they influence the target prioritization process? Methods: The main focus is on sequence- and structure-related computational methods for drugability prediction, giving an overview on their background as well as their bias and limitations with an emphasis on the structural biology point of view. Results/conclusion: Structural drugability assessment presents one criterion for prioritization of a target portfolio by enabling classification of targets into low, average, or high drugability.

Acknowledgements

The authors thank H Briem, J Günther, and A Müller-Fahrnow for carefully reading the manuscript and for inspiring discussions. and were prepared with Discovery Studio 2.0 (Accelrys, Inc., USA).

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.